

---

## Ngenic Q4 2022 - Review

During the fourth quarter, Ngenic entered several partnership agreements, received a breakthrough order, and scaled up its capacity. While recognizing that the company's cash balance was cSEK11m at year-end, we are maintaining our fair value range and base case.

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

**Ngenic Q4 2022 - Review**